What are the immunologically active components of bacille calmette-guerin in therapy of superficial bladder cancer?

International Journal of Cancer

Volumn 87, Issue 6, 2000, Pages 844-852

  Zlotta, Alexandre R ^a   Van Vooren, Jean Paul ^a   Denis, Olivier ^b   Drowart, Annie ^a   Daffé, Mamadou ^c   Lefèvre, Pascal ^b   Schandene, Liliane ^a   De Cock, Michel ^a   De Bruyn, Jacqueline ^b   Vandenbussche, Paul ^b   Jurion, Fabienne ^b   Palfliet, Kamille ^b   Simon, Jacques ^a   Schulman, Claude C ^a   Content, Jean ^b   Huygen, Kris ^b  

^a ERASME HOSPITAL   (Belgium)

^b PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6;

ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; RECEPTOR BLOCKING; TH1 CELL;

ANTIGENS, BACTERIAL; ANTIGENS, CD; ANTIGENS, CD56; BACTERIAL OUTER MEMBRANE PROTEINS; BCG VACCINE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; NEOPLASM PROTEINS; TH1 CELLS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0033836362     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000915)87:6<844::AID-IJC14>3.0.CO;2-5     Document Type: Article

References (28)

1. BCG immunotherapy of bladder cancer: 20 Years on
2. BCG's mechanism of action - Increasing our understanding
3. Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer
4. A new mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction
5. 13C NMR analyses
6. Effect of zinc deficiency on the appearance of two immunodominant protein antigens (32 kDa and 65kDa) in culture filtrates of mycobacteria
7. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value
8. + T lymphocytes
9. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon γ and tumor necrosis α
10. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell I dominant state
11. Spleen cell cytokine secretion in mycobacterium bovis BCG-infected mice
12. Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live Mycobacterium bovis BCG
13. + HLA-DR-restricted cytotoxic lymphocytes as well as nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat shock protein
14. Three different putative phosphate transport receptors are encoded by the Mycobacterium tuberculosis genome and are present at the surface of Mycobacterium bovis BCG
15. Structural features of the exocellular polysaccharides of Mycobacterium tuberculosis
16. Biosynthesis of the linkage region of the mycobacterial cell wall
17. Immunotherapy of bladder cancer
18. Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer
19. Anti-interleukin 2 receptor monoclonal antibodies. Respective role of epitope mapping and monoclonal antibody-receptor interactions in their antagonist effects on interleukin-2 dependent T cell growth
20. Molecular composition of the outermost capsular material of the tubercle bacillus
21. Non-major histocompatibility complex-restricted cytotoxic activity of blood mononuclear cells stimulated with secreted mycobacterial proteins and other mycobacterial antigens
22. Induction of interleukin 3 and tumor resistance by SSM, a cancer immunotherapeutic agent extracted from Mycobacterium tuberculosis
23. Cytotoxic γδ or αβ T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2
24. Interleukin-2: A cytokine at the interface of inflammation and immunity
25. An anti-neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine)
26. Evolution and clinical significance of the T-cell proliferative and cytokine response directed against the fibronectin-binding antigen 85 complex of bacillus Calmette-Guerin (BCG) during intravesical treatment of superficial bladder cancer
27. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacillus Calmette-Guerin (BCG) in patients with superficial bladder cancer
28. Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy